NICE recommends SGLT-2 inhibitors with metformin at diagnosis, citing major cardiovascular, renal, and mortality benefits.
People diagnosed with type 2 diabetes before age 40 face a higher lifetime risk of heart and kidney problems, so may benefit from adding another type of medicine called a GLP-1 receptor agonist (such ...
Most people with type 2 diabetes should be offered SGLT-2 inhibitors much earlier in their treatment, final NICE guidance has ...
New guidance from NICE recommends earlier use of SGLT-2 inhibitors and personalised treatment for people with type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results